The global CD28 market is growing as CD28-based research gains importance in cancer immunotherapy, autoimmune disease research, and T-cell-based treatments. Advances in monoclonal and bispecific antibodies, immunoassays, flow cytometry, and other research technologies are expanding applications related to CD28. Increasing biopharmaceutical investment and development of novel CD28-targeted therapies are further supporting opportunities across the global market.

The CD28 Market is projected to expand from US$ 1.45 Billion in 2025 to US$ 2.9 Billion by 2034, registering a CAGR of 8.02% during 2026–2034. CD28 is an important co-stimulatory receptor expressed primarily on T cells and plays a central role in regulating T-cell activation, proliferation, survival, and immune responses. Growing research into immune-mediated diseases, cancer immunotherapy, and targeted cellular therapies is increasing interest in CD28 biology and CD28-associated therapeutic approaches.

What is driving the market?

The expanding development of T-cell-based immunotherapies is a major factor supporting the growth of the CD28 market. CD28 signaling provides an important co-stimulatory pathway that works alongside T-cell receptor activation to strengthen immune-cell responses. This biological role has made CD28 an important area of investigation in oncology, immunology, and cellular therapy research.

Get a Sample PDF- https://www.theinsightpartners.com/sample/TIPRE00021838

The increasing use of immunotherapy for cancer treatment is creating opportunities for technologies and therapeutic approaches involving T-cell activation. CAR-T and other engineered T-cell therapies may incorporate intracellular signaling domains associated with CD28 to influence cellular activation and persistence. Continued research into these mechanisms is encouraging pharmaceutical and biotechnology companies to investigate ways of optimizing T-cell function.

CD28 is also being studied in relation to autoimmune and inflammatory disorders. Because excessive or inappropriate T-cell activation can contribute to immune-mediated diseases, researchers are evaluating CD28-related pathways as potential targets for therapeutic intervention. This broadens the market beyond oncology and creates opportunities across multiple areas of drug discovery.

Advances in molecular biology, protein engineering, antibody development, and immune-cell profiling are further supporting CD28 research. Improved understanding of immune signaling networks allows researchers to investigate CD28 interactions with other co-stimulatory and inhibitory pathways, potentially supporting the development of more targeted treatment strategies.

Which region leads?

North America represents a major market for CD28 research and therapeutic development, supported by its established biotechnology and pharmaceutical ecosystem. The region has extensive investments in cancer immunotherapy, cell therapy, molecular research, and biologics development. The presence of academic research institutions, clinical research organizations, biotechnology companies, and major pharmaceutical manufacturers further strengthens the ecosystem surrounding CD28-related research.

Europe is also an important region due to its strong biomedical research infrastructure and expanding development of advanced therapies. Research programs focused on immune regulation, oncology, and cellular therapies continue to generate demand for specialized antibodies, assays, reagents, and research tools associated with CD28.

Asia Pacific is expected to provide expanding opportunities as biotechnology investment, pharmaceutical research, and clinical development activities increase. Countries including China, Japan, South Korea, and India are strengthening capabilities in biologics and cell-based therapies. Increasing research activity in immunology and oncology is likely to support the adoption of CD28-related research technologies and therapeutic development platforms.

Which segment leads?

Research and therapeutic applications involving T-cell activation represent important areas of the CD28 market. CD28-related products are used in research to study immune-cell signaling, receptor interactions, cellular activation, and immune responses. Antibodies, recombinant proteins, assay systems, and other laboratory tools help researchers investigate CD28 expression and function.

The therapeutic segment is also gaining attention as pharmaceutical developers explore immune-modulating approaches. CD28 can serve as a component of engineered immune-cell therapies, while its signaling pathway can be investigated for controlling T-cell activity. The increasing sophistication of cellular therapies is therefore creating demand for technologies that can characterize and manipulate immune-cell behavior.

Cancer research remains a particularly important application area. Researchers are investigating how co-stimulatory signaling can influence the effectiveness, persistence, and functional characteristics of therapeutic T cells. At the same time, studies of immune tolerance and autoimmune disease are broadening the potential applications of CD28-targeted research.

Which companies are prominent?

The report identifies Atox Bio Ltd., Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc., Johnson & Johnson, TheraMAB LLC, Boster Biological Technology, Aviva Systems Biology Corporation, Biobyt Ltd., GeneTex, Inc., and ProteoGenix SAS as key companies analyzed in detail.

The competitive landscape includes pharmaceutical and biotechnology companies involved in therapeutic development as well as specialized life-science companies providing antibodies, recombinant proteins, research reagents, and molecular biology products. Their activities span discovery research, immune-cell characterization, therapeutic development, and laboratory applications.

Continued investment in immuno-oncology and advanced cell therapies is encouraging companies to strengthen their capabilities in immune signaling research. Partnerships between pharmaceutical developers, biotechnology firms, academic institutions, and specialized reagent providers can also contribute to the development and commercialization of CD28-focused technologies.

What is changing in 2026?

The CD28 market is increasingly being shaped by advances in engineered T-cell therapies and more precise immune-system modulation. Researchers are examining how different co-stimulatory signals influence T-cell behavior and how these pathways can be incorporated into next-generation therapeutic designs.

The growing sophistication of CAR-T and other cellular therapies is increasing interest in intracellular signaling components, including CD28-associated pathways. Researchers are also investigating combinations of co-stimulatory and immune-checkpoint mechanisms to better understand how therapeutic immune responses can be regulated.

Another emerging area is the development of more specialized research tools. Improved antibodies, recombinant proteins, multiplex assays, and cell-analysis platforms can help researchers characterize CD28 expression and signaling with greater precision. These tools are becoming increasingly relevant as immunology research moves toward more detailed cellular and molecular profiling.

What are the major investment opportunities?

Investment opportunities are emerging across CD28-targeted therapeutics, engineered immune-cell platforms, research reagents, and advanced immune-profiling technologies. Pharmaceutical and biotechnology companies developing next-generation immunotherapies may benefit from continued research into mechanisms that regulate T-cell activation and persistence.

Specialized suppliers can also find opportunities by developing high-specificity antibodies, recombinant CD28 proteins, assay kits, and analytical platforms for research and drug-development applications. As laboratories generate increasingly complex immunological datasets, technologies that combine molecular detection with advanced cellular analysis may gain greater relevance.

Another opportunity lies in the integration of CD28 research with broader immunotherapy development. Combining CD28-related research with studies of immune checkpoints, tumor microenvironments, cellular engineering, and biomarker identification could expand the potential applications of the market.

Going forward, commercialization opportunities will depend on clinical validation, therapeutic safety, research reproducibility, product specificity, regulatory requirements, and the ability to translate CD28 biology into effective applications across oncology, autoimmune disease, and advanced cellular therapies.

Related Reports @

Immunotherapy Drugs Market Share, Demand & Growth by 2034

Cancer Immunotherapy Market Growth, Analysis, and Forecast by 2031

About Us –

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish